• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Piramal Pharma Solutions New API Plant in Canada Now Online

    MG America Appoints Claudio Radossi as President

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Sartorius Expands Manufacturing Site in Tunisia

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Piramal Pharma Solutions New API Plant in Canada Now Online

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Grand Opening of Kodiak Sciences’ Bioconjugation Facility

    Vertex Expands Cell and Gene Therapy Footprint
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment

    WCG Appoints Sam Srivastava CEO

    AffyXell Expands Manufacturing Partnership with GenScript ProBio

    ABL and Odimma Therapeutics Enter Development Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Quotient Sciences

    Aphena Pharma Solutions

    Biosynth Carbosynth

    IDT Biologika
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Quotient Sciences

    Aphena Pharma Solutions

    Biosynth Carbosynth

    IDT Biologika
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Biocatalysis: An Indispensable Tool for API Synthesis

    Biocatalytic processing offers a wealth of advantages and should be evaluated during early-stage drug development.

    Biocatalysis: An Indispensable Tool for API Synthesis
    Biocatalysis: An Indispensable Tool for API Synthesis
    Benzion Dolitzky, VP R&D, Wavelength Pharmaceuticals06.07.21
    Biocatalysis is widely recognized to be one of the most powerful tools for organic synthesis due to its green credentials and its exquisite regio-, enantio-, and stereoselectivities. In recent years, it has benefited significantly from the development of a broad range of enabling technologies, leading biocatalysis to become an established methodology for efficient, sustainable manufacturing, especially within the drug development industry.

    A multitude of enzymes is now utilized for generating active pharmaceutical ingredients (APIs) and intermediates for their production, with such reagents offering numerous advantages compared to using traditional metal catalysts. One of the main benefits of biocatalysis is that it increases conversion efficiency for significantly higher yields with fewer by-products, equating to faster and more cost-effective production.

    By integrating biocatalysis into ongoing and newly launched projects, Wavelength Pharmaceuticals has shown that it is possible to reduce overall costs by as much as 30%. For these reasons, many pharmaceutical companies are choosing to evaluate biocatalytic processes during early-stage drug development to avoid missing opportunities for capitalizing on these gains.

    Biocatalytic processes leverage fundamental enzyme characteristics
    Enzymes play a pivotal role in the catalysis of many different bio-transformation reactions in nature, typically exerting their effects under mild, neutral conditions. This has led to them being evaluated as alternatives to traditional metal catalysts for driving various chemical transformations, where they have demonstrated huge success. Some of the first enzyme classes used as tools for organic synthesis were hydrolases (e.g. amidases, esterases, and lipases), alcohol dehydrogenases, and ketoreductases. These have since been joined by many other types of enzyme, including transaminases, oxidases, nitrilases, aldolases, and ammonia lyases, all of which perform distinct functions.

    An inherent advantage of using enzymes for synthetic chemistry is that they increase regio-, enantio-, and stereoselectivity for more efficient conversion of substrate to product. Additionally, because only small quantities of enzyme are required to catalyze a reaction, integrating them into production workflows can dramatically reduce raw material costs. In turn, these properties of enzymes translate to lower overall costs for manufacturing the final product. Further savings are realized through elimination of complicated protection/deprotection and activation steps, removal of the need for multiple, time-consuming purifications, and higher atom utilization to increase the percentage of reactants that become useful products.

    Enabling technologies have increased the scope of biocatalysis
    The development of various enabling technologies has been critical in expanding the potential of biocatalytic processing, as well as in promoting its uptake across the pharmaceutical industry. Improved gene mining techniques have permitted previously uncharacterized gene clusters to be discovered, while advances in heterologous expression and production have allowed the encoded enzymes to rapidly be scaled up and evaluated as tools for organic synthesis.

    Building on this progress, recombinant technologies have been key to optimizing the performance of biocatalytic reagents, for example by facilitating a reduction in the amount of enzyme needed to drive a reaction while at the same time increasing the yield. It has also been possible to prepare enzymes that can function effectively in organic solvents, thereby dramatically increasing the number of reactions possible. Other innovative technology developments have made immobilizing enzymes on solid supports like glass, silicon, or any other polymer more efficient. This not only makes it easier to remove enzyme residues from the desired product, but also ensures valuable high turnover enzymes can be reused multiple times without compromising their activity.

    Advantages of biocatalytic processing
    Biocatalytic processing offers many advantages over using conventional metal catalysts. The superior enantio- and regioselectivity of enzymes results in higher yields of purer product—typically comprising just a single enantiomer that has been modified on only a specific site. Moreover, the improved stereoselectivity further enhances product purity by ensuring that only one stereoisomer reacts where a mixture of stereoisomers is present. Atom utilization is also better with biocatalysis; where two or more moieties on the same molecule have the capacity to undergo a particular reaction, biocatalytic processing guarantees that one site is consistently chosen over the other. The incredible selectivity of enzyme catalysts consequently simplifies workflows by generating fewer by-products and reducing impurities to markedly decrease the total number of synthetic steps required.

    Another critically important benefit of biocatalytic processes is that they are far more eco-efficient than conventional methods. This is because enzymes, being originally derived from natural products, generally perform best under mild (often ambient) conditions. While reactions requiring the use of metal catalysts may necessitate heating to temperatures of 160oC, and/or cooling to -60oC or lower, enzyme-catalyzed reactions instead run at temperatures in the region of ~10 - 40oC. This so-called ‘green chemistry’ is much safer than metal-catalyzed approaches and can save vast quantities of reagents, consumables, organic solvents, and energy over the lifetime of a project to dramatically reduce waste and environmental burden. Biocatalysis also helps to avoid pollution and reduce global environmental impact as it helps minimize the use of rare metals which often require extensive mining and processing operations.

    Importance of evaluating biocatalytic processes during development
    With the chemical industry being one of the most polluting, global efforts are heavily focused on developing a more sustainable and greener footprint. The growing use of biocatalysis in pharmaceutical chemistry promises to deliver on this need, while also offering substantial cost savings and faster time to market for urgently needed therapeutics. However, to leverage these benefits, it is vital that biocatalytic processes be evaluated as early in the drug development life cycle as possible. Fortunately, the growing availability of diverse kits of enzyme classes can facilitate this process, allowing researchers to screen enzymes/biocatalysts in much the same way as traditional screening of metal catalysts is performed.

    A major advantage of identifying suitable biocatalysts early on is that it provides ample opportunity for optimization. For example, by using molecular modeling tools to achieve rapid de novo design of new enzymes, it may be possible to increase activity, enhance temperature stability, or improve solvent compatibility to better align with the process in question. As further tools are created to improve biocatalyst development, these can likewise be assessed for their capacity to add value to a project.

    Expedite biocatalysis development by partnering with an API CDMO
    Although biocatalysis is globally acknowledged to be a valuable means of ensuring greener, more sustainable manufacturing, its implementation has reached stasis after increasing steadily for the past 10 - 15 years. A possible reason for this is that developments within the biocatalysis field have fast outpaced existing knowhow, leaving some pharmaceutical companies unaware of the vast range of options available. Keeping abreast of both current and emerging developments within the field of biocatalytic processing is key when it comes to maintaining a competitive edge.

    One way of leveraging the many benefits of biocatalysis is to partner with an API CDMO offering comprehensive expertise and experience in developing and implementing such technology in GMP commercial production. With an up-to-date working knowledge of both established biocatalytic processes and the very latest techniques, a trusted API CDMO provider can offer a suite of technical capabilities, backed by highly trained personnel and a proven track record of consistent quality and regulatory compliance.

    Exploring biocatalysis options at the start of a project is a pragmatic operational strategy to achieve the right product, at the right quality, with exceptional efficiency. Such investment is by no means prohibitive and can reap substantial rewards that include shorter development timelines, lower costs, faster time to market, and game changing technological advantage for sustainable competitive edge. 

    Advantages of Biocatalytic Processing Compared to Using Metal Catalysts
    • Greater enantio-, regio-, stereo-, and stereoselectivity
    • Increased atom utilization
    • Reactions take place under mild conditions
    • Higher yields
    • Fewer synthetic steps
    • Green chemistry
    • Improved eco-efficiency
    • Reduced waste
    • Avoids pollution
    • Reduced consumption of organic solvents
    • Overcomes hazardous chemical reactions
    • Shorter development times
    • Lower costs



    Benzion Dolitzky, PhD, is Vice President of Research & Development at Wavelength Pharmaceuticals, a provider of advanced API solutions for sustainable, competitive advantage.
    Related Searches
    • Drug Development

    Related Content

      Trending
      • Cellipont Bioservices Expands Cell Therapy Facility | Contract Pharma
      • Biopharma Manufacturing Facility Construction | Contract Pharma
      • Next-Gen Lab Services | Contract Pharma
      • Pharma Development & Manufacturing Trends | Contract Pharma
      • Reviving Local Production Of Antibiotic Powders | Contract Pharma
      Breaking News
      • Piramal Pharma Solutions New API Plant in Canada Now Online
      • MG America Appoints Claudio Radossi as President
      • Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      • Sartorius Expands Manufacturing Site in Tunisia
      • BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      What Are You Reading?
      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 21
      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      P&G Closes HQ Due To Security Threat, Launches New Hair Care Line
      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Brook + Whittle's new acquisition, SunDance goes to HP and more
      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Weekly Recap: Kimberly-Clark to Expand Diaper, Wipes Production in Brazil; The Honest Company to Sell Diapers, Wipes at Walmart & More
      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most Read Stories This Week—May 21
      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login